New Combination Found Active in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

A combination of fludarabine, pixantrone, dexamethasone, and rituximab (FPD-R) achieved major durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) in a single-arm phase 1 dose-escalation study. The study identified a dose of 120 mg/m2pixantrone as the recommended dose for this regimen. The overall response rate with this regimen was 89%, and the regimen was well tolerated with no grade 3/4 cardiovascular adverse events. Grade 3/4 lymphopenia occurred, however, in 89% of patients and leukopenia in 79%.

 

The complete study can be read online in Cancer (http://onlinelibrary.wiley.com/doi/10.1002/cncr.26121/abstract).

Related Items
Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices
Meg Barbor, MPH
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
What Is the Role of Chemoimmunotherapy in the First-Line Treatment of CLL?
Wayne Kuznar
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
Genetic Profiling and Personalized Medicine in Myelodysplastic Syndromes
Meg Barbor, MPH
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
November 4, 2019 — Oncology News & Updates
Web Exclusives published on November 5, 2019 in Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Educating Your Patients About Daratumumab
Leslie Lauersdorf, ARNP
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
How to Handle Survivorship Care for Multiple Myeloma
Tiffany Richards, PhD, ANP-BC
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
How to Utilize New Mutliple Myeloma Drugs
Tiffany Richards, PhD, ANP-BC
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Preparing Your Patients for Side Effects
Tiffany Richards, PhD, ANP-BC
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Know Your Patients' Baselines
Tiffany Richards, PhD, ANP-BC
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Meeting the Needs of the Patient
Tiffany Richards, PhD, ANP-BC
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Last modified: July 22, 2021